https://scholars.lib.ntu.edu.tw/handle/123456789/467034
Title: | Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics | Authors: | Chen J.-J. Chan H.-Y. Chen C.-H. SUSAN SHUR-FEN GAU Hwu H.-G. |
Issue Date: | 2012 | Journal Volume: | 45 | Journal Issue: | 2 | Start page/Pages: | 64-71 | Source: | Pharmacopsychiatry | Abstract: | Objective: This study compares the efficacy of risperidone and olanzapine to that of first-generation antipsychotics (FGAs) in patients with schizophrenia, who failed to show a response to initial trials of FGAs. Method: This study was an 8-week treatment, randomized, rater-blind, active-control study with 3 treatment arms. 48 patients, who showed inadequate response to 1 FGA, were enrolled and randomized into risperidone, olanzapine, or FGA (haloperidol or trifluoperazine) groups. They were blindly assessed with the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression Scale-Severity, and the Extrapyramidal Symptom Rating Scale (ESRS) at baseline and biweekly. Results: All 3 groups demonstrated a significant decrease in the PANSS total, positive, and general scores from baseline to endpoint (p-values range from 0.003 to 0.021). There were no significant differences among the 3 groups in score changes. The olanzapine group had significant score reductions than the risperidone and FGAs groups in terms of the ESRS subjective total score and did not experience a significant increase in the dose of anticholinergics. The FGA group demonstrated that extrapyramidal syndrome (EPS) worsened under an increased dosage of anti-EPS drugs. Olanzapine was associated with significant body weight gain (2.694.0 kg, p=0.026), but there were no significant group differences on weight gain. Conclusions: Haloperidol or trifluoperazine demonstrated similar efficacy as risperidone or olanzapine for patients with schizophrenia who had failed their first trial with a FGA. Related double-blind, fixed dose studies with a larger sample size are needed to confirm the results of our study. ? Georg Thieme Verlag KG Stuttgart · New York. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/467034 | DOI: | 10.1055/s-0031-1291293 |
Appears in Collections: | 臨床醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.